BIOTON S.A.

Warsaw Stock Exchange BIO.WA

BIOTON S.A. Price to Earnings Ratio (P/E) on January 14, 2025: 114.55

BIOTON S.A. Price to Earnings Ratio (P/E) is 114.55 on January 14, 2025, a -13.90% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

BIOTON S.A. 52-week high Price to Earnings Ratio (P/E) is 139.25 on February 01, 2024, which is 21.56% above the current Price to Earnings Ratio (P/E).
BIOTON S.A. 52-week low Price to Earnings Ratio (P/E) is 101.53 on December 27, 2024, which is -11.37% below the current Price to Earnings Ratio (P/E).
BIOTON S.A. average Price to Earnings Ratio (P/E) for the last 52 weeks is 128.29.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Warsaw Stock Exchange: BIO.WA

BIOTON S.A.

CEO	Mr. Jeremy Launders
IPO Date	March 31, 2005
Location	Poland
Headquarters	ul. Poznanska 12
Employees	355
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.

Key trends

Past 5 years